{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:56:42Z","timestamp":1753891002490,"version":"3.41.2"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00484","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:55:02Z","timestamp":1554166502000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Editorial: Autoantibodies"],"prefix":"10.3389","volume":"10","author":[{"given":"Rikard","family":"Holmdahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falk","family":"Nimmerjahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fmed.2018.00296","article-title":"Diagnosis of autoimmune blistering diseases","volume":"5","author":"Witte","year":"2018","journal-title":"Front. Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2340\/00015555-3052","article-title":"Unmet needs in pemphigoid diseases: an international survey amongst patients, clinicians and researchers","volume":"99","author":"Lamberts","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/ni.3175","article-title":"Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus","volume":"16","author":"Tipton","year":"2015","journal-title":"Nat Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1084\/jem.20020165","article-title":"Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-\/-) mice","volume":"195","author":"Bolland","year":"2002","journal-title":"J Exp Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7881","DOI":"10.1073\/pnas.0915133107","article-title":"A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus","volume":"107","author":"Willcocks","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1073\/pnas.1017996108","article-title":"Genetic susceptibility to systemic lupus erythematosus protects against cerebral malaria in mice","volume":"108","author":"Waisberg","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/eji.200323794","article-title":"FcgammaRIIB deficiency with Fas mutation is sufficient for the development of systemic autoimmune disease","volume":"33","author":"Yajima","year":"2003","journal-title":"Eur J Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1126\/science.1124978","article-title":"Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication","volume":"312","author":"Pisitkun","year":"2006","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H","article-title":"Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus","volume":"41","author":"Herrmann","year":"1998","journal-title":"Arthritis Rheum"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1021\/acschemneuro.7b00319","article-title":"Anti-NMDA-receptor encephalitis: from bench to clinic","volume":"8","author":"Venkatesan","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3389\/fimmu.2017.00752","article-title":"Neuronal surface autoantibodies in neuropsychiatric disorders: are there implications for depression","volume":"8","author":"Zong","year":"2017","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"dmm035360","DOI":"10.1242\/dmm.035360","article-title":"Living inside the box: environmental effects on mouse models of human disease","volume":"11","author":"Sundberg","year":"2018","journal-title":"Dis Model Mech"},{"key":"B16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3389\/fmed.2018.00226","article-title":"The genetics of pemphigus vulgaris","volume":"5","author":"Vodo","year":"2018","journal-title":"Front Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1073\/pnas.1525448113","article-title":"Multiplexed autoantigen microarrays identify HLA as a key driver of anti-desmoglein and -non-desmoglein reactivities in pemphigus","volume":"113","author":"Sajda","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrrheum.2016.176","article-title":"Update on the genetic architecture of rheumatoid arthritis","volume":"13","author":"Kim","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jaut.2015.08.004","article-title":"Immunogenetics of systemic lupus erythematosus: A comprehensive review","volume":"64","author":"Ghodke-Puranik","year":"2015","journal-title":"J Autoimmun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3389\/fphys.2017.00236","article-title":"Daily moderate exercise is beneficial and social stress is detrimental to disease pathology in murine lupus nephritis","volume":"8","author":"Aqel","year":"2017","journal-title":"Front Physiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B23","first-page":"971","article-title":"The pathophysiological significance of nondesmoglein targets of pemphigus autoimmunity","volume":"134","author":"Vu","year":"1998","journal-title":"Arch Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fmed.2018.00218","article-title":"The evolving story of autoantibodies in Pemphigus vulgaris: development of the \u201csuper compensation hypothesis\u201d","volume":"5","author":"Sinha","year":"2018","journal-title":"Front Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/exd.12445","article-title":"Co-occurrence of autoantibodies in healthy blood donors","volume":"23","author":"Prussmann","year":"2014","journal-title":"Exp Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1136\/ard.2009.127100","article-title":"ANA screening: an old test with new recommendations","volume":"69","author":"Meroni","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"651058","DOI":"10.1155\/2012\/651058","article-title":"Automated indirect immunofluorescence evaluation of antinuclear autoantibodies on HEp-2 cells","volume":"2012","author":"Voigt","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/1529-0131(199709)40:9<1601::AID-ART9>3.0.CO;2-T","article-title":"Range of antinuclear antibodies in \u201chealthy\u201d individuals","volume":"40","author":"Tan","year":"1997","journal-title":"Arthritis Rheum"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/art.34380","article-title":"Prevalence and sociodemographic correlates of antinuclear antibodies in the United States","volume":"64","author":"Satoh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B30","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1080\/15287390600974593","article-title":"Antinuclear antibodies and bromoxynil exposure in a rural sample","volume":"70","author":"Semchuk","year":"2007","journal-title":"J Toxicol Environ Health A"},{"key":"B31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/brain\/awu310","article-title":"Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice","volume":"138","author":"Planagum\u00e0","year":"2015","journal-title":"Brain"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","article-title":"Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany","volume":"136","author":"H\u00fcbner","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study","volume":"129","author":"Joly","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fmed.2018.00139","article-title":"High index values of enzyme-linked immunosorbent assay for BP180 at baseline predict relapse in patients with bullous pemphigoid","volume":"5","author":"Koga","year":"2018","journal-title":"Front Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fmed.2018.00362","article-title":"Epidermolysis bullosa acquisita: The 2019 update","volume":"5","author":"Koga","year":"2018","journal-title":"Front Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3389\/fmed.2018.00306","article-title":"Perspective from the 5th International Pemphigus and Pemphigoid Foundation scientific conference","volume":"5","author":"Lee","year":"2018","journal-title":"Front Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-018-0896-1","article-title":"Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients","volume":"13","author":"Iwata","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s12016-009-8153-y","article-title":"High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases","volume":"38","author":"Ishii","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J Clin Invest"},{"key":"B44","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/eji.201344230","article-title":"Broad requirement for terminal sialic acid residues and FcgammaRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo","volume":"44","author":"Schwab","year":"2014","journal-title":"Eur J Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1365-2249.2010.04265.x","article-title":"Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris","volume":"162","author":"Mimouni","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1365-2249.2005.02947.x","article-title":"Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris","volume":"142","author":"Mimouni","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1093\/emboj\/20.12.3046","article-title":"EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG","volume":"20","author":"Collin","year":"2001","journal-title":"EMBO J"},{"key":"B49","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","article-title":"Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis","volume":"29","author":"Benamu","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.4049\/jimmunol.178.10.6514","article-title":"The alternative pathway in complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita","volume":"178","author":"Mihai","year":"2007","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"413","DOI":"10.4161\/mabs.19931","article-title":"Marketed therapeutic antibodies compendium","volume":"4","author":"Reichert","year":"2012","journal-title":"MAbs"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/exd.13335","article-title":"Signaling and targeted-therapy of inflammatory cells in epidermolysis bullosa acquisita","volume":"26","author":"Ludwig","year":"2017","journal-title":"Exp Dermatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.jid.2017.05.017","article-title":"The Syk tyrosine kinase is required for skin inflammation in an in vivo mouse model of epidermolysis bullosa acquisita","volume":"137","author":"N\u00e9meth","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.autrev.2009.01.011","article-title":"Apoptosis in pemphigus","volume":"8","author":"Schmidt","year":"2009","journal-title":"Autoimmun Rev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1468-3083.2009.03162.x","article-title":"The final destiny of acantholytic cells in pemphigus is Fas mediated","volume":"23","author":"Pacheco-Tovar","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0140-6736(03)12193-9","article-title":"Atopic dermatitis","volume":"361","author":"Leung","year":"2003","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.atherosclerosissup.2017.05.043","article-title":"Immunoadsorption for treatment of severe atopic dermatitis","volume":"30","author":"Wegner","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"B59","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:55:04Z","timestamp":1554166504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2019.00484"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00484","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2019,4,2]]},"article-number":"484"}}